Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC
Hemogenyx Pharmaceuticals announces a strategic investment from Prevail Partners, , totaling $350,000 (£269,000) through a subscription for ordinary shares at $0.075 per share, a 275% premium to the closing price on October 1, 2024. The subscription will take effect in March 2025, supporting the planned HEMO-CAR-T pediatric study.
Additionally, Hemogenyx's subsidiary has signed an amendment with Prevail InfoWorks, Inc. to provide clinical services for the upcoming Phase I study of anti-FLT3 CAR-T cells in pediatric patients with relapsed/refractory acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The study is expected to commence in the first half of 2025.
The investment from Prevail Partners will largely cover the initial payment to InfoWorks for the pediatric study services.
Hemogenyx Pharmaceuticals annuncia un investimento strategico da parte di Prevail Partners, per un totale di $350.000 (£269.000) tramite un sottoscrizione di azioni ordinarie a $0.075 per azione, un premio del 275% rispetto al prezzo di chiusura del 1° ottobre 2024. La sottoscrizione avrà effetto a marzo 2025, supportando il previsto studio pediatrico HEMO-CAR-T.
In aggiunta, la sussidiaria di Hemogenyx ha firmato un emendamento con Prevail InfoWorks, Inc. per fornire servizi clinici per il prossimo studio di Fase I delle cellule CAR-T anti-FLT3 in pazienti pediatrici con leucemia mieloide acuta (AML) e leucemia linfoblastica acuta (ALL) in fase di recidiva/resistenza. Si prevede che lo studio abbia inizio nella prima metà del 2025.
L'investimento da parte di Prevail Partners coprirà principalmente il pagamento iniziale a InfoWorks per i servizi dello studio pediatrico.
Hemogenyx Pharmaceuticals anuncia una inversión estratégica de Prevail Partners, que totaliza $350,000 (£269,000) a través de una suscripción de acciones ordinarias a $0.075 por acción, un 275% de prima sobre el precio de cierre del 1 de octubre de 2024. La suscripción entrará en vigor en marzo de 2025, apoyando el estudio pediátrico HEMO-CAR-T planificado.
Además, la subsidiaria de Hemogenyx ha firmado una enmienda con Prevail InfoWorks, Inc. para proporcionar servicios clínicos para el próximo estudio de Fase I de células CAR-T anti-FLT3 en pacientes pediátricos con leucemia mieloide aguda (AML) y leucemia linfoblástica aguda (ALL) en recaída/refractaria. Se espera que el estudio comience en la primera mitad de 2025.
La inversión de Prevail Partners cubrirá en gran medida el pago inicial a InfoWorks por los servicios del estudio pediátrico.
헤모제닉스 제약는 프리베일 파트너스의 전략적 투자를 발표했습니다. 총액은 $350,000 (£269,000)이며, 주당 $0.075로 보통주를 구독하는 방식입니다. 이는 2024년 10월 1일 종가에 대해 275%의 프리미엄입니다. 구독은 2025년 3월부터 시행되며, 계획된 HEMO-CAR-T 소아 연구를 지원합니다.
또한, 헤모제닉스의 자회사는 프리베일 인포웍스, Inc.와 계약 수정안을 체결하여 재발/내성 급성 골수성 백혈병(AML) 및 급성 림프모구 백혈병(ALL) 소아 환자를 위한 항-FLT3 CAR-T 세포의 1상 연구에 대한 임상 서비스를 제공할 예정입니다. 연구는 2025년 상반기에 시작될 것으로 예상됩니다.
프리베일 파트너스의 투자는 소아 연구 서비스에 대한 인포웍스에 대한 초기 지급을 주로 지원할 것입니다.
Hemogenyx Pharmaceuticals annonce un investissement stratégique de Prevail Partners d'un montant de 350 000 $ (£269 000) par le biais d'une souscription d'actions ordinaires à 0,075 $ par action, ce qui représente une prime de 275 % par rapport au prix de clôture du 1er octobre 2024. La souscription prendra effet en mars 2025, soutenant l'étude pédiatrique HEMO-CAR-T prévue.
De plus, la filiale de Hemogenyx a signé un amendement avec Prevail InfoWorks, Inc. pour fournir des services cliniques pour la prochaine étude de Phase I sur les cellules CAR-T anti-FLT3 chez des patients pédiatriques atteints de leucémie myéloïde aiguë (LMA) et de leucémie lymphoblastique aiguë (LLA) en rechute/réfractaire. L'étude devrait commencer dans la première moitié de 2025.
L'investissement de Prevail Partners couvrira en grande partie le paiement initial à InfoWorks pour les services de l'étude pédiatrique.
Hemogenyx Pharmaceuticals kündigt eine strategische Investition von Prevail Partners in Höhe von 350.000 US-Dollar (£269.000) an, die durch ein Abonnement für Stammaktien zu je 0,075 US-Dollar erfolgt, was einem Aufpreis von 275% gegenüber dem Schlusskurs am 1. Oktober 2024 entspricht. Das Abonnement tritt im März 2025 in Kraft und unterstützt die geplante HEMO-CAR-T-Pediatric-Studie.
Darüber hinaus hat die Tochtergesellschaft von Hemogenyx eine Ergänzung mit Prevail InfoWorks, Inc. unterzeichnet, um klinische Dienstleistungen für die bevorstehende Phase-I-Studie von anti-FLT3 CAR-T-Zellen bei pädiatrischen Patienten mit rezidivierter/refraktärer akuter myeloischer Leukämie (AML) und akuter lymphoblastischer Leukämie (ALL) bereitzustellen. Die Studie wird voraussichtlich in der ersten Hälfte von 2025 beginnen.
Die Investition von Prevail Partners wird größtenteils die Erstzahlung an InfoWorks für die Dienstleistungen der pädiatrischen Studie abdecken.
- Strategic investment of $350,000 at a 275% premium to current share price
- Upcoming Phase I pediatric clinical study for HEMO-CAR-T
- Partnership with experienced CRO Prevail InfoWorks for clinical trial management
- Potential acceleration of regulatory timeline through real-time data analytics
- None.
Prevail Partners, LLC to invest again in Hemogenyx Pharmaceuticals
Prevail InfoWorks, Inc. to act as Clinical Research Organization (CRO) for upcoming Phase I pediatric clinical study
LONDON, UNITED KINGDOM / ACCESSWIRE / October 2, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces tha tPrevail Partners, LLC ("Prevail Partners"), an investment fund, has agreed to invest a total of
The subscription will take effect in March 2025 ahead of the planned HEMO-CAR-T pediatric study. This will follow the initiation of the adult clinical trial in HEMO-CAR-T at the MD Anderson Cancer Center, Texas, which is expected to commence later this year. The agreement governing the subscription contains customary warranties from the Company and Prevail Partners.
The Company's wholly owned subsidiary, Hemogenyx Pharmaceuticals LLC, has also signed an amendment to the Master Service and Technology Agreement ("MSTA"), (the "Amendment") with Prevail InfoWorks, Inc. ("InfoWorks"), the Philadelphia, PA based Clinical Research Organization ("CRO"), and affiliate of Prevail Partners. Infoworks is already contracted by the Company in relation to the existing planned HEMO-CAR-T clinical trials in adult patients.
Under the terms of the Amendment, InfoWorks is to provide clinical services and technologies for the Company's upcoming Phase I study of its anti-FLT3 chimeric antigen receptor-redirected T cells ("CAR-T cells") in pediatric subjects with relapsed/refractory acute myeloid leukemia (AML) and a subset of acute lymphoblastic leukaemia (ALL). The Amendment will come into effect in March 2025.
Services to be provided under the terms of the Amendment include clinical site coordination, project management, data management, clinical monitoring, and pharmacovigilance (safety management) services, and the use of InfoWorks' integrated real-time data analytics platform, the Single Interface®, for clinical support and real-time data analysis. The MSTA has an initial term of 26 months, and Hemogenyx Pharmaceuticals LLC has agreed an initial statement of works relating to the Phase I pediatric AML/ALL study. The pediatric study is expected to commence in the first half of 2025.
The subscription funds received from Prevail Partners will in large part defray the payment made by the Company for the first stage of the work to be undertaken by InfoWorks under the Amendment.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "As we seek to bring the curative power of cell therapies to children suffering from the otherwise largely incurable life-threatening diseases, AML and ALL, we are very confident in Prevail InfoWorks' ability to coordinate our Phase I clinical trial in pediatric relapsed/refractory AML and ALL. Their operational experience and expertise will enable a smooth execution of the study, while their specialization in real-time data integration and analytics will ensure fast, reliable data access to lower our clinical risk and potentially speed up our regulatory timeline. Prevail Partners' strategic investment in the Company, once again at a price very substantially above the Company's existing share price, demonstrates their confidence in our CAR-T program and in our ability to execute the upcoming clinical study."
Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukaemia and a subset of acute lymphoblastic leukaemia in children. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the Company to a significant value inflection point through the completion of its planned clinical trial."
About AML and CAR-T Therapy
AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than
CAR-T therapy is a treatment in which a patient's own T-cells, a type of immune cell, are modified to recognize and kill the patient's cancer cells. The procedure involves: isolating T-cells from the patient; modifying the isolated T-cells in a laboratory using a CAR gene construct (which allows the cells to recognize the patient's cancer); amplifying (growing to large numbers) the newly modified cells; and re-introducing the cells back into the patient.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
|
|
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
|
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
About Prevail Partners, LLC
Prevail Partners, LLC is a corporate strategic investment fund investing in clinical stage therapeutics companies. More information is available at https://prevailpartners.com/.
About Prevail InfoWorks, Inc.
Prevail InfoWorks, Inc. is a global full-service CRO/FSP and one-stop-shop for clinical trial services and systems. More information is available at https://prevailinfoworks.com/.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on accesswire.com
FAQ
What is the amount and terms of Prevail Partners' investment in Hemogenyx Pharmaceuticals (HOPHF)?
When will Hemogenyx Pharmaceuticals (HOPHF) begin its HEMO-CAR-T pediatric clinical study?
What services will Prevail InfoWorks provide for Hemogenyx Pharmaceuticals' (HOPHF) pediatric clinical trial?
What is the target patient group for Hemogenyx Pharmaceuticals' (HOPHF) upcoming pediatric clinical trial?
